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Abstract
Background: Diagnosis of tuberculosis (TB) remains problematic despite many new advanced
diagnostic methods. A reliable and rapid diagnostic test, which could be performed in any standard
pathology laboratory, would help to obtain definitive early diagnoses of TB. In the present study
we describe a prospective evaluation for demonstrating Antigen (Ag) 85 complex in the sera from
TB patients.
Methods: Indirect ELISA, employing monoclonal antibodies (mAb) against the purified Ag 85
complex, was used to demonstrate Ag 85 complex in sera from TB patients. Serum samples were
obtained from 197 different groups of patients: confirmed TB {n = 24}, clinically diagnosed TB {n =
104}, disease controls {n = 49} and healthy controls {n = 20}. Receiver operating curve (ROC) was
used to calculate the cut off value and comparison between TB and non-TB groups were done by
the chi-square test.
Results: The indirect ELISA method, using an mAb against Ag 85 complex, yielded 82% sensitivity
(95% confidence interval [CI] 67 to 93%) and 86% specificity (95% CI, 57 to 98%) for the diagnosis
of TB. The serum positivities for Ag 85 complex in cases of confirmed and clinically diagnosed TB
patients were 96% (23/24) and 79% (82/104) respectively, while the positivity for patients in the
non-tuberculosis group was 14% (10/69).
Conclusion: The detection of Ag 85 complex in sera from TB patients by indirect ELISA using
mAb against purified Ag 85 complex gives a reliable diagnosis and can be used to develop an
immunodiagnostic assay with increased sensitivity and specificity.
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Background
One third of the global population is believed to be
infected with M. tuberculosis bacilli (MTB) complex, the
causative agent of tuberculosis (TB) [1]. The recent
increase of this endemic disease is due to its occurrence in
association with human immunodeficiency virus (HIV);
this co-infection has aggravated the existing situation [2].
Fast and accurate diagnosis of TB is very important ele-
ment in global health measures to control the disease [3].
Traditionally, diagnosis of TB rests on sputum examina-
tion and cultures for acid-fast bacilli (AFB) [4]. However,
the sensitivity of the sputum smear for AFB is very poor
and facilities for mycobacterial culture are often scarce in
regions where tuberculosis is common; and even when
they are available, culture results are frequently usually
too late to affect initial management [5].
The Mantoux Tuberculin Skin Test (TST), which uses five
tuberculin units of purified protein derivative, is the
standard routine method for detecting M. tuberculosis
infection. Since TST is generally used to determine asymp-
tomatic infection, the false-negative rate cannot be calcu-
lated. A negative TST does not rule out TB disease in a
child. False-positive reactions to TST are often attributed
to asymptomatic infection by non-tuberculous mycobac-
teria in the environment. The relatively low sensitivity and
specificity of TST makes the test very useful for people at
high risk of TB infection or disease but undesirable for
people at low risk [6,7]. The QuantiFerron TB test was
recently developed to overcome some of the limitations of
the TST; however, the 12 hrs time limit on whole blood
processing is a major weakness in terms of its applications
in a reference laboratory setting [8]. Recently Diagnostic
polymerase chain reaction (PCR) using specific primers as
markers for M. tuberculosis is not performed correctly in all
clinical laboratories and shows variable sensitivity and
specificity [9]. Many serological assays have been tried,
but nearly all have failed to improve upon the time-hon-
ored sputum smear and culture approach [10-14].
We have previously demonstrated the presence of a 30-
kD-protein antigen in cerebrospinal fluid (CSF) from con-
firmed and suspected tuberculous meningitis (TBM)
patients [15]. This 30 kD protein band was excised from
the gel, digested with trypsin and analyzed by liquid chro-
matography tandem mass spectrometry (LC-MS/MS) and
two-dimensional polyacrylamide gel electrophoresis
(2DPAGE). Together, these studies identified the compo-
nents of the TBM-specific 30 kD antigen: two mycobacte-
rial antigens, Rv 3804c and Rv1886c (Ag 85 A and B
respectively, both members of Ag 85 complex), and one
host-derived protein (immunoglobulin [Ig] Kappa light
chain VLJ region; accession no. BAC01690.1) [16]. Con-
currently, antibodies generated against the 30-kD protein
were found to react with most CSF samples from TBM
patients.
Ag85 complex comprises three related major secretary
proteins of M. tuberculosis, which have been the focus of
extensive research for several years: Ag85A (31 kD), Ag85B
(30 kD) and Ag85C (31.5 kD). These antigens have also
been demonstrated in the sputum of pulmonary TB
patients [17]. Various forms of Ag 85 complex have previ-
ously been evaluated for antibody detection in extra-cen-
tral nervous system TB [18-20]. In the present study,
serum specimens from patients with TB were examined
for the presence of M. tuberculosis Ag 85 complex by a sen-
sitive and specific indirect ELISA protocol developed in
our laboratory.
Methods
Study subjects
We prospectively selected serum samples from 128 active
TB patients (81 male, 47 female; age 13–63 years) from
inpatient and outpatient services at the Tuberculosis
Center, Government Medical College (GMC), Nagpur and
Central India Institute of Medical Sciences, Nagpur. In
addition, selected patients admitted to the hospital for
defined acute or chronic non-TB diseases (n = 49) includ-
ing asthma (n = 10), neurological disorders (n = 09), res-
piratory symptoms (n = 08), gastrointestinal symptoms (n
= 8), non-specific fever (n = 8), pneumonia (n = 2), bron-
chitis (n = 2), lung cancer (n = 1) and lung infection (n =
1), as well as 20 healthy volunteers (age 10–56) with no
signs of clinical impairment and normal chest radio-
graphs, were included as controls. All subjects were nega-
tive for HIV. Serum samples were obtained from almost
all patients before initiation of AKT and were stored at -
20°C until they were tested. In India, BCG vaccination is
given within one week of the birth of child; all subjects
included in the study had been vaccinated with BCG.
Samples were collected from all study groups for which
patient's consent was obtained.
To diagnose active TB, sputum microscopy was done on
two serial sputum samples by staining with Ziehl Neelson
Stain as per the guidelines of India's Revised National
Tuberculosis Control Programme. However, Of the 128
patients, only 24 patients had initial positive results for
AFB in sputum samples. Final cultures for M.tuberculosis
on Lowenstein-Jensen medium obtained after 6 weeks
were positive. TB was confirmed if AFB and/or culture of
sputum specimens were positive for M. tuberculosis. When
both tests were negative, the patients were diagnosed by
clinical symptoms. Clinical suspicion of tuberculosis was
based on minimum of 3 symptoms of the following a)
Chronic cough with or without expectoration/hemopty-
sis/chest pain of more than 2–3 weeks or past history of
TB b) Fever more than 2–3 weeks c) Progressive unex-BMC Infectious Diseases 2007, 7:74 http://www.biomedcentral.com/1471-2334/7/74
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plained weight loss d) loss of appetite e) night sweats.
Radiographic features supporting the clinical diagnosis
considered were lung parenchymal infiltration mainly
involving apical and/or mid zone, miliary shadows and
pleural effusion. Along with the above mentioned clinical
features any one radiological feature was considered suffi-
cient as supportive evidence. Ultrasound examination of
chest was done in suspected cases of pleural effusion,
which was also utilized for diagnostic pleural tap. Sputum
samples of 41 TB patients with clinical diagnosis was
available but were all negative to culture/AFB staining. All
patients received anti-TB drug (not covered under DOT)
in absence of any other therapy. Daily dosages were given
as isoniazid 300 mg, rifampicin 450 mg or 600 mg,
pyrazinamide 1.5 g or 2.0 g and ethambutol 25 mg/kg for
the first 2 months. In the next 2 months rifampicin 450
mg or 600 mg, isoniazid 300 mg and ethambutol were
given followed by ethambutol, rifampicin 450 mg or 600
mg and isoniazid 300 mg for the next 4 months.
Cases were followed at regular interval for a period of 9
months. Improvement in all subjects was judged clinically
(Improvement in cough, fever, appetite, wieight gain etc)
radiographic evidence (resolution of lesion on repeat
chest × ray after 3 months of standard anti-TB treatment).
All subjects including clinically diagnosed patients
improved clinically and responded well to anti-Koch
treatment (AKT) after three months of standard anti-
tuberculosis treatment. The Central India Institute of
Medical Sciences Ethical Committee, Nagpur, India
approved the study and all the analyses were performed
double blinded.
Specimens
Sputum specimens for ordinary examination by AFB and
cultivation were obtained over three consecutive days. The
sputum sample was digested and decontaminated with
2% sodium hydroxide and then processed for further
investigation. Ziehl-Neelson acid fast staining was used to
confirm the presence of acid-fast bacilli. Venous blood
was collected from all the patients and control subjects.
Blood was allowed to clot, and after centrifugation (1000
× g, 10 min) the serum was separated and stored at -20°C
until it was used.
Antigen and antibody
The purified Ag 85 complex and monoclonal antibodies
against this complex (CS-90) were obtained from Colo-
rado State University, USA through the TB Research Mate-
rials and Vaccine Testing Contract (NO1-AI-40091).
Indirect ELISA protocol
Prior to patient sampling, the assay was standardized by
incubating purified Ag 85 complex with the CS-90 mAb at
different dilutions (1–500 ng/ml). Indirect ELISA was per-
formed as described by Kashyap et al. [16]. Serum samples
of 100 µl (1:200) from TB patients and control subjects
were added to the microtiter wells and blocked with 0.5%
bovine serum albumin (BSA) in phosphate buffered
saline (PBS). After washing with PBS, the mAb (1:2000)
was added and the plates were incubated at 37°C for 60
min. The wells were washed, and then secondary antibody
(goat anti-rabbit IgG-HRP, 1:10000) was added and incu-
bated for 60 min at 37°C. After another wash with PBS,
100 µl of TMB/H2O2 substrate was added to the wells and
incubated at room temperature for about 10 min. The
reaction was then stopped with 100 µl of 2.5 N H2SO4.
The absorbance of each well was read at 450 nm. Samples
with absorbance > 0.18 were considered positive. Each
sample was tested in triplicate.
Western blotting
Serum proteins at 30 µg/lane were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) [26] and transferred to polyvinyledineflouride
(PVDF) membranes by electroblotting at 100 V for 3
hours. The membrane was treated with 50% v/v methanol
immediately prior to and after the electroblotting. The
membrane was then blocked with 0.5% BSA in PBS at
37°C for 60 min. After blocking, the membrane was
washed with PBS (3 × 10 min), probed with CS-90 mAb
(1:2000) and incubated at 37°C for 60 min. The mem-
brane was then washed with PBS, followed by addition of
1:10,000 diluted affinity-purified anti-rabbit IgG conju-
gated to horseradish peroxidase (Genei, Bangalore, India)
and incubated at 37°C for 60 min. After incubation, the
membrane was washed extensively with PBS followed by
addition of tetramethylbenzidine-hydrogen peroxide
(TMB/H2O2), which enabled the antibody reaction to be
visualized.
Statistical analysis
The sensitivities and specificities of developed Indirect
ELISA based test for diagnosis of TB and Non-TB group
were calculated. The positive and negative predicative val-
ues were calculated by using different rates of TB preva-
lence. Receiver operating curve (ROC) was used to
calculate the cut off value and comparison between TB
and non-TB groups was done by the chi-square test.
Results
Different concentrations of Ag 85 complex antigen were
titrated with the antibody and a standard curve was plot-
ted. Figure 1 shows the increase in absorbance at 450 nm
with increasing concentration of Ag 85 complex antigen
during the standardization of the indirect ELISA method.
Table-1 shows the occurrence of Ag 85 complex antigen in
sera from the TB and non-TB groups as determined by the
indirect ELISA method along with mean absorbance (withBMC Infectious Diseases 2007, 7:74 http://www.biomedcentral.com/1471-2334/7/74
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range). Cutoff value of 0.18 was determined for ELISA test
using ROC analysis. The serum positivities for Ag 85 com-
plex antigen in cases of confirmed and clinically diag-
nosed TB patients were 96% (23/24) and 79% (82/104)
respectively, while the positivity for patients in the non-
tuberculosis group was 14% (10/69). No Ag 85 complex
was detected in the healthy control group. Overall, the
indirect ELISA method yielded 82% sensitivity (95% con-
fidence interval [CI] 67 to 93%) and 86% specificity (95%
CI, 57 to 98%) for the diagnosis of TB using the mAb to
Ag 85 complex. The mean absorbance value of Ag 85 com-
plex antigen in the TB patients was 0.42 ± 0.22 (range
0.03–0.92), significantly higher than in the non-TB group
(0.16 ± 0.08; range 0.01–0.36; P < 0.001). There was a sig-
nificant difference in the mean Ag 85 complex antigen
activity between the confirmed TB patients (0.64 ± 0.22;
range 0.22 – 0.92) and the clinically diagnosed TB
patients (0.37 ± 0.19; range 0.03 – 0.92;P  < 0.0001)
(Table-1).
Box plots of the Ag 85 complex activity in sera from con-
firmed and clinically diagnosed TB patients, non-TB dis-
ease patients and healthy control group with cut off value
are shown in figure 2 together with the 90th percentile
range, 75 th and 25 th percentiles. The serum samples
from the TB and non-TB patients were separated by one-
dimensional electrophoresis and blotted on to PVDF
membranes. Figure 3 depicts immunoblotting with spe-
cific rabbit antibodies against Ag 85 complex antigen. The
serum of a TB patient (lane 1) shows reactivity for Ag 85
complex antigen, which was absent in case of a non-TB
patient (lane 2).
Discussion
Various immunoassays for detecting antigen or antibody
in serum samples with different sensitivities and specifici-
ties have been developed. However, despite extensive
work on the diagnosis of TB, only few diagnostic tests are
available [21-24]. We previously isolated a 30 kD protein
from CSF of TBM patients and characterized it using LC-
MS/MS analysis and N-terminal sequencing. These studies
demonstrated that the 30 kD protein contains Rv3804c
(Ag 85A) and Rv1886 c (Ag 85 B), both components of
the Ag 85 complex, and one host-derived protein immu-
noglobulin [Ig] kappa light chain VLJ region; accession
no.BAC01690 [4,17].
In the present study, using an indirect ELISA method, we
have conducted a prospective study for demonstrating Ag
85 complex in sera from TB patients using a mAb against
the complex. The data demonstrate that the positivities for
Ag 85 complex antigen in cases of confirmed and clini-
cally diagnosed TB patients were 96% (23/24) and 79%
(82/104) respectively, while the positivity for patients in
the non-tuberculosis group was 14% (10/69). The reason
for these false positive results is unclear but latent infec-
tion cannot be ruled out. However, Ag 85 complex was
not detected in any of the healthy control group. Overall,
the indirect ELISA method yielded 82% sensitivity and
86% specificity for the diagnosis of TB using the mAb
against Ag 85 complex.
There are not many reports about the detection of Ag 85
complex in sera from TB patients. Bentley-Hibbert et al.
Table 1: Demonstration of Ag 85 complex in sera from tuberculosis and non-tuberculosis patients by indirect ELISA method using the 
mAb against purified Ag 85 complex along with mean absorbance (with range)
Patient group Positivity for Ag 85 complex 
(cutoff of 0.18)
Negativity for Ag 
85 complex
Absorbance 
(Mean ± 2SD)
Range
Tuberculosis group (n = 128) 105 (82.03%) 23 (17.96%) 0.42 ± 0.22 0.03 – 0.92
Confirmed (n = 24) (AFB & ulture positive) 23 (95.83%) 1 (4.17%) 0.64 ± 0.22 0.22 – 0.92
Clinically diagnosed (n = 104) (AFB & ulture negative) 82 (78.84%) 22 (21.16%) 0.37 ± 0.19 0.03 – 0.92
Non-tuberculosis group (69) 10(14. 49%) 59 (85. 51%) 0.16 ± 0.08 0.01 – 0.36
Disease Control(n = 49) 10 (20.40%) 39 (79.59%) 0.17 ± 0.09 0.01 – 0.36
Healthy Control(n = 20) 0 (0%) 20 (100%) 0.13 ± 0.05 0.02 – 0.21
The data are expressed as mean ± SD.
Absorbance at 450 nm with increasing concentration of Ag  85 complex in the standardization of the indirect ELISA  method Figure 1
Absorbance at 450 nm with increasing concentration of Ag 
85 complex in the standardization of the indirect ELISA 
method.
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[25] measured the complex antigen in serum and urine by
a mAb-based dot-immunobinding assay in 56 patients
and controls with known skin test reactivity. The median
serum Ag 85 complex levels were higher in patients with
active TB than in patients with non-TB pulmonary disease
or in healthy controls, suggesting that measurement of cir-
culating Ag 85 complex might be developed into a diag-
nostic test for active tuberculosis infection. Similarly,
Sánchez-Rodríguez et al. [26] determined the IgG antimy-
cobacterial antibody response to Ag 85 complex antigen
and showed a sensitivity of 72% and a specificity of 100%.
Overall, these findings support our results, suggesting that
detection of Ag85 complex might be developed into a
diagnostic test for TB. However, one study has shown
lower sensitivity with respect to examination of circulat-
ing Ag85 complex in patients with active TB [27].
Several previous studies have reported that Ag 85 complex
is the immunodominant antigen in all mycobacteria
including lepra bacillus and environmental mycobacteria,
so it may give false results with other mycobacterial dis-
eases [28]. However, when we evaluated the expression of
Ag 85 complex in sera from twenty-five leprosy patients
using the same protocol, the results were negative in all
but one patient (unpublished observations). In any case,
even though the lepra bacillus belongs to the same genus
as the tuberculosis organism and has Ag 85 complex, it
produces a clinical picture of leprosy that differs vastly
from that of TB. Therefore, it is not difficult to rule out lep-
rosy clinically as distinct from other infections. Moreover,
the presence of Ag 85 complex in environmental myco-
bacteria and BCG would be unlikely to influence the inter-
pretation of our results, because almost all the controls
(i.e. non-TB patients and healthy subjects) included in the
study were vaccinated with BCG and exposed to the same
environment.
In this study, we have used an indirect ELISA method to
detect M. tuberculosis Ag 85 complex in sera from TB and
non-TB patients. Indirect ELISA is technically very simple
and affordable in underdeveloped and developing coun-
tries. In the absence of sophisticated methods, such as
molecular methods based on nucleic acid amplification
and T cell-based immunological tests, indirect ELISA has
become widely accepted for diagnosing tuberculosis and
would potentially decrease the cost of the antibody rea-
gent compared to the traditional sandwich ELISA system.
Conclusion
Detection of Ag 85 complex in TB patient sera by indirect
ELISA using a mAb to Ag 85 complex gives reliable diag-
nosis and does not give false results with other non-tuber-
culosis diseases. It could be used for developing an
immunodiagnostic assay with increased sensitivity and
specificity. Such a test would be rapid, sensitive and cost-
effective and could be performed easily in any standard
pathology laboratory.
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